All results / Stories / Joel Russell


FDA Agrees to Review Rival Neupogen Drug

The Food and Drug Administration accepted an application on Thursday by a rival drug maker to approve a copy-cat version of Neupogen, one of the biggest money-makers for Amgen Inc.

Anteing Up

Sanjay Sabnani spent $5 million to add social gaming to the thousands of forums run by his tiny CrowdGather Inc. Was that a bet worth making?

Q&A: Sanjay Sabnani hopes investors like his plan to combine forums and social games.

Amgen Researchers Discover Cholesterol Gene

A subsidiary of Amgen Inc. has discovered a rare variation in the sequence of a human gene that gives people a significant reduction in levels of “bad” cholesterol and lowers the risk of heart attacks, the company announced Wednesday.

In Volatility, ‘We Want to Run Counter Cyclical’

The investment side has become much more of a commodity.

The CEO of SEO

Bruce Clay has made himself the go-to name in search engine optimization. He also got his sister $1 million with 12 hours work.

Q&A: Bruce Clay pioneered the search engine optimization business.

Tease photo

Camarillo Attorneys In the Clouds

LightGabler specializes in employment law, counseling and litigation.

Amgen to Pay $6 Billion Tax Bill to Repatriate Cash

Amgen Inc. expects pay between $6 billion and $6.5 billion in taxes as it repatriates money from overseas operations, the company said Friday in a filing with the Securities and Exchange Commission.

Master of Business

David Nazarian has big plans for CSUN following his $10 million gift – the school’s largest ever.

Q&A: David Nazarian discusses his $10 million donation to CSUN, the largest in school history.

Health Care Special Report: Hospitals Flash Forward

High-tech advances are about to revolutionize patient care, but it will take challenging the status quo.

Local executives describe their vision for the “Hospital of the Future.”

VALLEY INSIDER

‘Audience Fatigue’ Expert

VALLEY INSIDER

Scientific American

Peter Derycz used to be a ‘library slave’ in college. Now, his Research Solutions digs up research papers for tech companies.

Peter Derycz went from starving student to CEO of a publicly traded company.

Tease photo

YEAR of the DISRUPTORS

Technology presents challenges and opportunities for professionals in the financial services sector.

Despite its buttoned-down image, the financial services industry has entered a period of turmoil caused by new technology, consumer expectations and consolidation in addition to regular capital market volatility.

Valley Firm Counting On Vegas Cards

Barcelona Marketing is not bluffing with its hand in poker network.

Media: Alan Semsar wants to make TV poker the next big thing – again.

Afrezza for Sale in U.S.

MannKind Corp. announced on Tuesday that its Afrezza brand of inhalable insulin is now available by prescription at U.S. pharmacies.

7 Over Seventy - Jim Dunn

Profiles - Jim Dunn: Look into the lives of local executives who still work into their seventh decade and beyond.

He’s the Law

Lancaster Mayor R. Rex Parris is a wealthy personal injury attorney who has some innovative ideas about how cities can work with businesses.

Q&A: From solar energy investments to pit-bull control, R. Rex Parris brings unconventional thinking to the mayor’s office in Lancaster.

Tease photo

50 Fastest Growing Private Companies 2017: Goldco Precious Metals

An inside look at some of the top ranking companies.

Growth a Challenge at Women-Owned Businesses

Management: Top firms enjoy success, but owners pay price in long hours.

STORY: Women-owned businesses across the Valley area report growth in 2012.

Tease photo

Sanguine BioSciences Gathers Seed Funding

Sanguine BioSciences Inc., a company that collects blood for use in medical research, has closed its seed funding round with $10 million.

Bulk Buys to Microloans

VEDC plans to leverage a grant into a national $20 million microlending program.